MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress-Reference-Cited by-同舟云学术

MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress

Published:2014-05-29 Issue:1 Volume:13 Page:
ISSN:1476-4598
Container-title:Molecular Cancer
language:en
Short-container-title:Mol Cancer

Author:

Felder Mildred,Kapur Arvinder,Gonzalez-Bosquet Jesus,Horibata Sachi,Heintz Joseph,Albrecht Ralph,Fass Lucas,Kaur Justanjyot,Hu Kevin,Shojaei Hadi,Whelan Rebecca J,Patankar Manish S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Molecular Medicine

Link

https://link.springer.com/content/pdf/10.1186/1476-4598-13-129.pdf

Reference177 articles.

1. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M: CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer. 2005, 15: 679-691. 10.1111/j.1525-1438.2005.00130.x.

2. Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, Babaian R, Bast RC, Dowell B, Esteva FJ, Haglund C, Harbeck N, Hayes DF, Holten-Andersen M, Klee GG, Lamerz R, Looijenga LH, Molina R, Nielsen HJ, Rittenhouse H, Semjonow A, Shih Ie M, Sibley P, Soletormos G, Stephan C, Sokoll L, Hoffman BR, Diamandis EP: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008, 54: e11-e79. 10.1373/clinchem.2008.105601.

3. Seltzer V, Drukker BH, Gillespie BW, Gossfeld LM, Grigsby PW, Harvey HA, Hendricks CB, Hummel S, Makuch RW, Monaco GP, Parham GP, Sawyers CL, West RJ, Alberts DS, Anderson B, Averette HE, Bast RC, Christian MC, Colombo N, Creasman WT, John P, Curtin JP, Gershenson DM, Hoskins WJ, Karlan BY, Kramer BS, Markman M, McGuire WP, Ozols RF, Pecorelli S: NIH consensus conference: ovarian cancer: screening, treatment, and follow-up. NIH consensus development panel on ovarian cancer. JAMA. 1995, 273: 491-497. 10.1001/jama.1995.03520300065039.

4. Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J: Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 2004, 96: 487-488.

5. Vasudev NS, Trigonis I, Cairns DA, Hall GD, Jackson DP, Broadhead T, Buxton J, Hutson R, Nugent D, Perren TJ: The prognostic and predictive value of CA-125 regression during neoadjuvant chemotherapy for advanced ovarian or primary peritoneal carcinoma. Arch Gynecol Obstet. 2011, 284: 221-227. 10.1007/s00404-010-1655-2.

Cited by 353 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Selective determination of an ovarian cancer biomarker at low concentrations with surface imprinted nanotube based chemosensor;Bioelectrochemistry;2024-06

2. A Revised Molecular Model of Ovarian Cancer Biomarker CA125 (MUC16) Enabled by Long-read Sequencing;Cancer Research Communications;2024-01-31

3. Prognostic Significance of preoperative serum CA125, CA19-9, CA72-4, CEA, and AFP in Patients with Endometrial cancer;2024-01-26

4. Pancreatic and Biliary Tract Cancers;Gastrointestinal Oncology ‐ A Critical Multidisciplinary Team Approach 2e;2024-01-23

5. High-Grade Serous Ovarian Cancer—A Risk Factor Puzzle and Screening Fugitive;Biomedicines;2024-01-19